Drugs / ARO-MUC5AC
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05292950 | Jun 2022 → Nov 2024 | asthma, chronic obstructive pulmonary disease | Arrowhead Pharmaceuticals | Terminated | No outcome recorded Stop: Business |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2022-03-24 | Arrowhead Pharmaceuticals | Regulatory Arrowhead Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-MUC5AC for Treatment of Muco-Obstructive Lung Diseases arrowheadpharma.com ↗
An application for approval of the clinical trial was submitted to a local Ethics Committee and to the New Zealand Medicines and Medical Devices Safety Authority for review by the Standing Committee on Therapeutic Trials. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2022-07-05 | Arrowhead Pharmaceuticals | Arrowhead Pharmaceuticals Initiates Phase 1/2a Studies for Two Pulmonary Candidates ARO-MUC5AC and ARO-RAGE arrowheadpharma.com ↗ |
| 2022-03-24 | Arrowhead Pharmaceuticals | Arrowhead Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-MUC5AC for Treatment of Muco-Obstructive Lung Diseases arrowheadpharma.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ARO-MUC5AC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05292950 ↗ |
| Route | Inhaled | “single or multiple doses of ARO- MUC5AC by inhalation of nebulized solution” NCT05292950 ↗ |